New and better information for scientists, toward novel therapeutic strategies in cancer and congenital disorders. We design, we produce and we provide research tools for gene expression analysis at the ribosomal level
We are engaged with customers at every step of the way.
IMMAGINA BioTechnology s.r.l (The Ribosome Company) is a company operating in the MedTech sector of Genomics, Proteomics and Enabling Technology, that is incubated in the Laboratory for Biomolecular Sequence and Structure Analysis for Health in Trento (Italy). Our mission is to deliver high-quality solutions to assess translational control of gene expression and translatome-associated biomarkers.
IMMAGINA was founded in 2014, when the founders started to develop RiboLaceTM, the only technology that enables the capture of active ribosomes.
RiboLace is on the market from November 2018. Starting from 2016, thanks to the levering investments from private investors (of whom the most relevant one is BAN/TN, TBA network and the Herman Hauser Investment) and the recruitment of new experienced scientists, two new technologies for translatome analysis (AHARIBOTM and circAID-p-seqTM) were developed and finally launched on the market at the end of 2019.
IMMAGINA offers a platform of products with the potential to accelerate the path toward the discovery of novel therapeutic strategies.
We deliver high-quality solutions to assess translational control of gene expression and translatome-associated biomarkers.
The Ribosome Company
IMMAGINA designed, developed and commercialize a Platform Technology focused on Ribosome to isolate and analyse active ribosomes and the associated RNA molecules
IMMAGINA ambition is to deliver smart solutions for truer gene expression analysis in research and pharma labs, to support life science worldwide. We are working to provide you with the best picture of gene expression. Because the message is only part of the story.
Supporters & partners
Wants to join the startup company to help accomplish our mission?
The European Training Network named ROPES (ROle of EPitranscriptomics in DiseasES) has been granted in the framework of the Horizon 2020 Marie Skłodowska-Curie Action for Innovative Training Network (ITN). The project aims to unravel the role of epitranscriptomics in diseases and to exploit it for novel therapies. ROPES, awarded with 3M € from the European Commission, will start on December 2020 and will recruit Early Stage Researchers to perform innovative research projects in cooperation with leading universities in Europe and the United States of America.
ROPES will recruit twelve early-stage researchers, one of which at IMMAGINA BioTechnology Srl. More info and application here: Horizon 2020 - Marie Sklodowska-Curie Actions ROPES position in IMMAGINA
Immagina Biotech and Tri-I Biotech announce distribution agreement
Immagina Biotech is very pleased to announce the appointment of Tri-I Biotech Inc as its official distributor in Taiwan to further expand and grow its business operations in Asia.
Online webinar: Spinal Muscular Atrophy: lost in translation?
IMMAGINA BIOTECHNOLOGY and TomaLab are excited to host a series of free live scientific webinars. During the webinars, prestigious speakers will present their recent researches carried out by the use of IMMAGINA BIOTECH products for the study of translational control of gene expression and diseases.
Officially announcing the collaboration between IMMAGINA Biotechnology and Genexa!
We are working together to develop a powerful data analysis tool for the only product available for 3’ phospho-RNA sequencing with ONT platform, CircAID-p-seq! Genexa is a service provider for bioinformatic analyses based in Zurich, Switzerland. Genexa’s services are centered around the analysis of third- and next-generation genomics data and the development of novel data […]